These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6369278)

  • 21. Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis of EORTC GU Group Trial 30843. European Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group.
    de Voogt HJ; Studer U; Schröder FH; Klijn JG; de Pauw M; Sylvester R
    Eur Urol; 1998; 33(2):152-8. PubMed ID: 9519356
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA; Lange PH; Janknegt RA; Abbou CC; deGery A
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
    Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial.
    Janknegt RA; Abbou CC; Bartoletti R; Bernstein-Hahn L; Bracken B; Brisset JM; Da Silva FC; Chisholm G; Crawford ED; Debruyne FM
    J Urol; 1993 Jan; 149(1):77-82; discussion 83. PubMed ID: 7678043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
    Bubley GJ; Carducci M; Dahut W; Dawson N; Daliani D; Eisenberger M; Figg WD; Freidlin B; Halabi S; Hudes G; Hussain M; Kaplan R; Myers C; Oh W; Petrylak DP; Reed E; Roth B; Sartor O; Scher H; Simons J; Sinibaldi V; Small EJ; Smith MR; Trump DL; Wilding G
    J Clin Oncol; 1999 Nov; 17(11):3461-7. PubMed ID: 10550143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunoassayable prostate-specific acid phosphatase in peripheral and bone marrow sera compared in diagnosis of prostatic cancer patients.
    Vihko P; Kontturi M; Lukkarinen O; Vihko R
    J Urol; 1982 Oct; 128(4):739-41. PubMed ID: 6183458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
    Hetherington JW; Siddall JK; Cooper EH
    Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum osteocalcin in monitoring bone metastases in advanced prostatic cancer.
    Marcellini M; De Carli P; Abbolito MR; Mainiero G; Cantiani R
    Eur Urol; 1992; 21 Suppl 1():102-4. PubMed ID: 1385126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.
    Reikerås O; Due J; Sundsfjord JA
    Int Urol Nephrol; 1988; 20(1):51-4. PubMed ID: 3283071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Criteria for evaluating patient responses to treatment modalities for prostatic cancer.
    Slack NH; Murphy GP
    Urol Clin North Am; 1984 May; 11(2):337-42. PubMed ID: 6375069
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate tumour markers and differentiation grade in prostatic cancer.
    Haapiainen RK; Permi EJ; Rannikko SA; Voutilainen PE; Alfthan OS
    Br J Urol; 1990 Dec; 66(6):635-8. PubMed ID: 1702339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostatic acid phosphatase in serum and bone marrow in patients with prostatic carcinoma.
    Fossà SD; Skinningsrud A; Kaalhus O; Engeset A
    Br J Urol; 1983 Jun; 55(3):306-11. PubMed ID: 6850249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?
    Morris MJ; Autio KA; Basch EM; Danila DC; Larson S; Scher HI
    Semin Oncol; 2013 Jun; 40(3):375-92. PubMed ID: 23806501
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon.
    Drugs R D; 2006; 7(3):197-201. PubMed ID: 16752945
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carcinoma of the prostate: the treatment of bone metastases by radioactive phosphorus (32P).
    Ariel IM; Hassouna H
    Int Surg; 1985; 70(1):63-6. PubMed ID: 4019087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical assessment of solid phase immunoadsorbent assay of human prostatic acid phosphatase.
    Bauer HW; Schmeller NT
    Urology; 1984 Mar; 23(3):247-51. PubMed ID: 6199879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of metastatic endocrine-unresponsive carcinoma of the prostate gland with multiagent chemotherapy: indicators of response to therapy.
    Paulson DF; Berry WR; Cox EB; Walker A; Laszlo J
    J Natl Cancer Inst; 1979 Sep; 63(3):615-22. PubMed ID: 381751
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates in prostate carcinoma.
    Adami S
    Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A; Sommer F; Ohlmann CH; Schrader AJ; Olbert P; Goecke J; Engelmann UH
    Cancer; 2004 Sep; 101(5):948-56. PubMed ID: 15329902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone scintigraphy and serum phosphatases in the detection and follow-up of bone metastases in prostatic cancer.
    Liewendahl K; Alfthan O; Ikonen T; Ruutu M; Rannikko S
    Scand J Urol Nephrol; 1984; 18(3):181-5. PubMed ID: 6494827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.